-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-32 Basic Mechanisms and Significance of Altered Splicing in Cancer and Hematology

Program: Scientific Program
Session: RNA in Normal and Malignant Hematopoiesis
Saturday, December 5, 2020, 11:55 AM-12:00 PM

Chris B. Burge, MD, PhD

Biology, Massachusetts Institute of Technology, Cambridge, MA

Disclosures: Burge: Remix Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Arrakis Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees.

See more of: RNA in Normal and Malignant Hematopoiesis
See more of: Scientific Program
Previous Presentation | Next Presentation >>